Unraveling the clonal hierarchy of somatic genomic aberrations by Prandi, Davide et al.
 
Unraveling the clonal hierarchy of somatic genomic aberrations
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Prandi, D., S. C. Baca, A. Romanel, C. E. Barbieri, J. Mosquera,
J. Fontugne, H. Beltran, et al. 2014. “Unraveling the clonal
hierarchy of somatic genomic aberrations.” Genome Biology 15
(8): 439. doi:10.1186/s13059-014-0439-6.
http://dx.doi.org/10.1186/s13059-014-0439-6.
Published Version doi:10.1186/s13059-014-0439-6
Accessed February 17, 2015 2:28:19 AM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:13347406
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-
of-use#LAAMETHOD Open Access
Unraveling the clonal hierarchy of somatic
genomic aberrations
Davide Prandi
1, Sylvan C Baca
2,3,4, Alessandro Romanel
1, Christopher E Barbieri
5,6,8, Juan-Miguel Mosquera
6,8,
Jacqueline Fontugne
6, Himisha Beltran
7,8, Andrea Sboner
6,8,9, Levi A Garraway
2,3,4, Mark A Rubin
5,6,8
and Francesca Demichelis
1,8,9*
Abstract
Defining the chronology of molecular alterations may identify milestones in carcinogenesis. To unravel the
temporal evolution of aberrations from clinical tumors, we developed CLONET, which upon estimation of tumor
admixture and ploidy infers the clonal hierarchy of genomic aberrations. Comparative analysis across 100
sequenced genomes from prostate, melanoma, and lung cancers established diverse evolutionary hierarchies,
demonstrating the early disruption of tumor-specific pathways. The analyses highlight the diversity of clonal evolution
within and across tumor types that might be informative for risk stratification and patient selection for targeted
therapies. CLONET addresses heterogeneous clinical samples seen in the setting of precision medicine.
Background
Cancer arises from initiating cells (clones) that undergo
intense evolutionary selection during disease progression
and can be widely altered during treatment. The tumor
cell evolutionary process may lead to subclonal diver-
gence resulting in genetic and molecular heterogeneity.
Computational approaches to establish maps of cancer
evolution might inform clinical risk stratification and treat-
ment strategies. Analysis strategies have been developed to
address tumor DNA purity and cancer cell ploidy, but there
remains a gap for the analysis of minimally aberrant or
highly heterogeneous tumors.
Over the past years, several methods have been de-
veloped to quantify DNA admixture and ploidy from
high density single-nucleotide polymorphism (SNP)
array data [1-4] that utilize the relative abundance of
specific allele signal (B allele frequency (BAF)) and the
tumor over normal signal ratio (referred to as Log R) to
measure the complexity of the underlying cellular popula-
tion. Global optimization methods are applied to find the
configuration of DNA admixture and ploidy that better
account for the observed values of BAF and Log R. More
recent tools [5-9] exploit the rich statistical properties of
massively parallel sequencing to provide base-pair data
resolution. Using germline heterozygous SNP loci (here-
after called informative SNPs), tumor purity and ploidy
are estimated analyzing allelic fraction (AF) values (that is,
the fraction of sequencing reads supporting the reference
base) in a way resembling the use of BAF data in SNP
arrays. Subclonal alterations will appear as outliers from
the computed admixture and ploidy.
All these tools apply a global approach (that is, the AF
(or BAF) values are all thrown into an inference algo-
rithm that eventually returns DNA purity and ploidy).
Global methods are well-suited for tumor samples with
fairly homogenous genomic aberrations (high ratio of
clonal versus subclonal lesions). In the clinical setting,
where tumor samples might exhibit heterogeneity due to
progression or subsequent to multiple lines of treatment,
and for tumor types that undergo structural changes
such as ‘chromoplexy’ events in prostate cancer (that is,
abundant DNA rearrangements and deletions that arise
in a highly interdependent manner) [10], these approaches
m a yp r o v es u b o p t i m a la st h e yi g n o r et h eg e n o m i cd i v e r s i t y .
These observations prompted us to develop a second
generation tool based on local (in contrast to global)
optimization where estimates of purity and ploidy are derived
from few clonal events (Figure 1). We noted that the AF
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http://genomebiology.com/2014/15/8/439values of the informative SNPs within a somatic deletion re-
sult from the composition of signal from three cell popu-
lations: (i) non-tumor cells (contributing to the DNA
admixture); (ii) tumor cells without the deletion; and (iii)
tumor cells harboring the deletion (that is, a subclonal dele-
tion given (ii) and (iii)). By modeling the probability distribu-
tion of the observed AFs, we compute a local estimate of the
DNA admixture (1 - DNA purity) that accounts for both nor-
mal cell admixture and subclonal tumor cell population.
After estimating local admixture values for all deletions
across the genome, only selected lesions (from the most
clonal side of the spectrum) contribute to the computation
of the tumor sample global admixture. In the presence of
homogenously aberrant genomes (Figure 1, top), global and
local approaches result in similar estimates; for heterogeneous
genomes (Figure 1, bottom), the local approach focused on
selected lesions (blue arrows in Figure 1) leads to more realis-
tic estimates. Here, we present the full implementation of
CLONET (CLONality Estimate in Tumors) and study the
clonality of somatic aberrations from whole genome sequen-
cing (WGS) data across 3 tumor types comprising 55 indi-
viduals with primary prostate cancer [10], 24 metastatic
melanomas [11], and 21 lung adenocarcinomas [12].
Results
Clonality assessment of aberrations from sequencing reads
We reasoned that the reads mapped into a genomic win-
dow can be partitioned in two sets: one set includes reads
that equally represent parental chromosomes (copy number
neutral reads); and the other set contains reads from only
one parent chromosome (active reads). There are four main
steps that, starting from neutral read counts, allow infer-
ence of clonality of any genomic window. First, we estimate
the percentage of neutral reads within a genomic segment
independently of its Log R value. Second, we use the Log R
value to relate the neutral reads percentage with a local esti-
mate of DNA admixture. Local estimates are then aggre-
gated to estimate global admixture and clonality of somatic
copy number aberrations (SCNAs). Third, aneuploidy ge-
nomes are identified and the analysis corrected accordingly.
Finally, we extend the analysis to point mutations (PMs)
and structural rearrangements (REARRs) in a coherent
manner. In the following we will briefly detail each step.
For each genomic segment Seg, the expected AF of the
informative SNP in Seg has bimodal distribution that re-
lates to the composition of the DNA sample; the distance
between the two modes is proportional to the percentage
of neutral reads β (see Materials and methods). The ex-
pected distribution of the AF (Figure 2A) varies accord-
ingly with β and Nref, which is the proportion of reference
base reads in the allele represented by active reads. For
each input segment Seg, optimization based on swarm
intelligence [13] finds a β that minimizes the difference
between the expected and the observed AF distribution
(see Materials and methods). Then, the Log R of Seg al-
lows computing a local estimate of the admixture. If Seg
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Figure 1 Local versus global approaches to clonality analysis. The local optimization approach to compute global admixture (1 - purity) and ploidy
is schematically explained and compared with a global optimization approach on two cancer samples with different levels of lesion heterogeneity. Copy
number neutral regions show nominal AF of 0.5; AFs of mono-allelic deletions depend on lesion clonality and on global admixture. Arrows
point to lesions used by global (red) or local (blue) approach. For sample 1 showing a profile compatible with clonal cell population (that is,
each lesion demonstrates approximately the same AF value), the two approaches return equivalent estimates. For sample 2 (high heterogeneity) the
local approach focuses on lesions with the highest level of clonality (blue arrows), resulting in a realistic estimate of the sample admixture.
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centage of reads deriving from cells that do not harbor the
deletion (see Materials and methods) and relates to a local
estimate of the percentage of admixed cells, Adm.local,a s
(proof in Additional file 1):
Adm:local ¼
β
2−β
ð1Þ
Reasoning that the signal from normal cells is uniform
along the genome, local admixture values are then clus-
tered, and the lowest median value among all the clusters
determines the global admixture (Adm.global) of the sam-
ple. Reasoning that the more the local admixture value
differs from the global one the more Seg is subclonal, the
clonality of Seg, ClSeg, is computed as the percentage of
tumor cells in a sample harboring Seg. If Seg is a gain,
Equation 1 extends by rescaling the percentage of neutral
reads β to recover the percentage of reads sequenced from
cells that does not harbor the gain of Seg (Figure 2B;
Materials and methods). Bi-allelic deletions are treated
separately; if the deletion is clonal, its AF distribution
has binomial distribution (β =1) and represents only
DNA admixture, but in case of subclonality, the value of
Figure 2 CLONET key elements. (A) For each genomic segment, the AF distribution of informative SNPs follows a bimodal distribution that
depends on the proportion of reference bases in the active allele (Nref) and on the percentage of neutral reads (β) (left panel; 60X coverage data
used For high values of β the distribution becomes unimodal as a function of the coverage (right panel; Nref=0.5). (B) For a genomic segment,
the relationship between Adm.local and β is a hyperbola whose parameter values are governed by the segment copy number (CN). (C) Genomic
segment representation in the β versus Log R space depends on the combination of the copy number of the parental alleles. Aneuploidy causes
a shift while Adm.global results in shrinkage of the allowed subspaces. Violet dots indicate genomic segments with equal number of parental
alleles (that is, 1/1, 2/2, 3/3,…). (D) The sketch illustrates the alternative allele proportion (AP) of a mono-allelic REARR defined by the genomic
coordinates bp1 and bp2 The aberrant allele is represented by two types of reads: reads with abnormal insert size (gray) and reads that span both
sides of a breakpoint (orange for bp1 and red for bp2). The non-aberrant allele exhibits two matching classes: paired-end crossing reads where
one end maps entirely to one side and the other entirely to the other side correspond to aberrant gray reads. Single end reads that span the
breakpoint (overlapping) are a complementary match to aberrant orange and red reads. The clonality is proportional to the proportion of aberrant
reads around the breakpoint junction. Ad hoc quality filters are applied for removing sequencing artifacts around REARRs (right inset). First, the
non-aberrant allele coverage is the minimum between the coverage in bp1 and bp2. Then, a REARR is adequate for analysis if the AP is statistically
indistinguishable if we consider overlapping or crossing reads (proportion test with limit value 0.1).
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do not harbor the deletion (Additional file 2).
Aneuploidy causes a shift in the Log R versus β space
of a sample (Figure 2C). In any genomic segment with
an empty active reads set (neutral copy number seg-
ment) each allele has the same number of copies, and its
β is 1 by definition. The ploidy of a sample is the shift
in the Log R values of the neutral segment that best
accounts for the observed Log R values. Log R data are
then corrected for both ploidy and Adm.global to
achieve better estimates of the segment copy number
(Figure S2A-C in Additional file 3).
Clonality estimates of PMs build on the assumption
that reads supporting the alternative allele are represen-
tative of the amount of tumor DNA harboring the muta-
tion. In particular, the proportion of reads supporting
the alternative allele (AP) of a 100% pure and clonal
hemizygous PM has symmetric binomial distribution.
The Adm.global value represents the percentage of reads
from admixed cells that have to be ignored to compute
the correct value of the AP. A PM is subclonal when its
corrected AP has a low probability to be clonal (type I
error <0.05). The same principle applies to REARRs by
properly selecting reads from rearranged tumor cells.
The total number of reads that span both sides of a
breakpoint defining a REARR [14] is a proxy of the num-
ber of cells harboring the rearrangement (Figure 2D).
After removing reads representative of global admixture,
the difference between the expected and the observed
proportion of reads supporting the alternative allele is
proportional to the subclonality of the considered REARR
(Additional file 1).
Inferring the order of mutations in a tumor sample
The assessment of the clonality of each somatic aberration
enables the deconvolution of the sequence of oncogenic
events that occur during tumor initiation or progression.
Assuming that clonal alterations originated prior to
subclonal alterations within the same tumor, we exam-
ined pairs of genes that are aberrant in the same sample
and across multiple tumors to determine the direction-
ality of the clonal-subclonal hierarchy. However, dif-
ferent error sources may introduce a bias into the
distribution of the AF that could lead to inaccurate
clonality estimates. To minimize the number of false
positives (clonal aberrations called subclonal), we com-
pute the estimation uncertainty around β (Figure 3A)
and propagate it to clonality values (see Materials and
methods). Error management enables robust compari-
son of aberration clonality across different tumor sam-
ple data. We then apply the following algorithm to
determine the progression on somatic aberrations: if a
clonal aberration A1 and a subclonal aberration A2 co-
occur within the same sample S, we assume that A1 has
been acquired before A2 in S and we say that A1 pre-
cedes A2 in S. To then derive the rule that links aberra-
tion A1 and A2, the same dependency has to be found
consistently across many samples. This strategy can pro-
duce an evolution path draft (that is, a pictorial represen-
tation of the potential temporal relations among somatic
aberrations observed in a sample set (Figure 3B)). In the
presence of adequate sample size and frequencies of co-
occurring aberrations, the statistical significance of the
relation between A1 and A2 can be assessed by testing
the null hypothesis that two aberrations are independent
(that is, A1 precedes A2 or A2 precedes A1 are equally
likely) and consider a binomial distribution B(n,p)w i t h
number of trials n equals the number of samples where
A1 is clonal and A2 is subclonal or vice versa, and success
probability P=0.5 (binomial test with 5% significance
would require a minimum of 6 out of 6 samples where A1
precedes A2).
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Figure 3 Building the evolution path. (A) For each genomic segment, the uncertainty value around β is a function of the number of informative
SNPs and of the mean local coverage. (B) Tumor evolution paths are built from ordered aberrations consistently observed in multiple samples. On the
left, arrows indicate ordered aberrations based on clonality estimates within the same tumor; three distinct aberrations (orange, green, and blue) precede
a fourth one (red). Ordered aberrations that find statistical support (as recurrent in multiple samples) contribute to the tumor evolution path (right).
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To assess if the coverage depth typical of large scale se-
quencing experiments (around or below 100X for WGS)
has an effect on clonality estimates of SCNAs or PMs,
we first queried MiSeq ultra-deep sequencing (approxi-
mately 65,000X) data generated from a set of 18 aber-
rant genes from 7 tumor samples analyzed in this study
and observed excellent agreement in downstream clonal-
ity calls for deletions (Cochran test, P =1) [10]. Notably,
CLONET did not assign clonality values to aberrations
in which MiSeq does not confirm WGS-based AP values.
Next, we focused on a set of study PMs and assessed high
correlation of AP values between WGS and MiSeq (mean
coverage >143,000X) data (Figure S3A in Additional file 4;
Table S1 in Additional file 5) (Pearson’sr=0 . 7 3 ,P< 10e-3),
suggesting altogether that the study coverage does not sig-
nificantly impact the ability to assess aberration clonality.
In order to validate the clonality status of more com-
plex structural genomic aberrations, specifically gene rear-
rangements and homozygous deletions, we turned to in
situ tests on human tumor samples. As proof of principle,
we first demonstrated the ability to assess rearrangement
clonality focusing on well-characterized prostate-specific
clonal REARRs involving ERG and TMPRSS2 [15]. Separ-
ate clonality analyses of both TMPRSS2-ERG REARRs and
of the accompanying 3 Mb interstitial deletion [16] in two
prostate tumors (P03-2345 and PR-09-146) demonstrated
perfect agreement (Figure 4A; Figure S3B in Additional
file 4). Next, we validated by fluoresce in situ hybridization
(FISH) analyses two subclonal REARR calls, involving a
genomic area 86 kb upstream of MSR1 (8p22) in patient
PR-2525 (Figure 4B) and SPRY2 (13q31.1) in patient PR-
3042 (Figure S4A in Additional file 6).
Finally, we validated in situ a homozygous deletion
along 5q spanning CHD1 that was predicted to be sub-
clonal. Figure 4C shows the sequencing data information
utilized by CLONET to infer the subclonal bi-allelic de-
letion in patient sample PR-2741 as confirmed by FISH
(Figure 4D). The prediction highlights a relatively small
subclonal bi-allelic deletion (Figure 4C, region 2) within
a larger clonal mono-allelic deletion (Figure 4C, regions
1 and 3), suggesting that selective evolutionary pressure
is acting on the genomic region. Patient PR-2525 dem-
onstrated a similar subclonality pattern at the CHD1
locus (Figure S4B in Additional file 6).
Comparison of CLONET and ABSOLUTE
We compared Adm.global predictions for prostate can-
cer and melanoma samples with calls reported in the
original manuscripts [10,11] (data for lung not publicly
available) using a widely used computational method,
ABSOLUTE [5], that implements a global estimation
approach. Overall agreement was observed (Figure S5A,
B in Additional file 7) in both datasets (Pearson’sr≥ 0.8,
P <10e-5). Not surprisingly, CLONETallowed for larger
fractions of admixture calls compared with ABSOLUTE
(98% versus 74% in prostate and 92% versus 88% in mel-
anoma) as the local approach better handles samples
with low ratios of clonal to subclonal SCNAs. The aver-
age ratio across cases only handled by CLONET is 1.73
versus average ratios across cases handled by both of
5.72 and 6.88 for prostate and melanoma samples, re-
spectively. We further tested CLONET performance on
whole exome sequencing (WES) data using an independ-
ent cohort of 108 prostate samples [17] (Pearson’sr=0 . 7 4 ,
P<10e-15; Figure S5C in Additional file 7).
In terms of ploidy assessment we noted significant dif-
ferences in the melanoma dataset where CLONET tends
to undercall polyploidy (Figure S5D in Additional file 7).
Where our conservative approach might definitely intro-
duce false negative calls, we identified cases where close
inspection of allele-specific data is not necessarily compat-
ible with ABSOLUTE original calls of polyploidy [11]; for
example, ME049T (Figure S5E in Additional file 7), where
the relative distances among Log R peaks are more com-
patible with a diploid genome.
Comparative analysis reveals different mechanisms of
tumor deregulation
We analyzed a total of 17,645 losses, 4,753 gains, 7,728
PMs, and 1,504 REARRs (Figure S6A in Additional file 8)
and a panel of more than 23,000 genes from the RefSeq
database [18]. Figure 5A summarizes the distribution of
clonality across tumor types and aberrations. We com-
pared the mean number of events classified as clonal or
subclonal by means of the proportion test with Benjamini-
Hochberg false discovery rate (FDR) correction (Figure 5B;
Table S2 in Additional file 5). We observed that deletions
are more heterogeneous than gains in prostate and lung
cancer (corrected P-values <10e-6 and <10e-21, respect-
ively) and, interestingly, melanoma samples showed the
opposite behavior (corrected P-value <10e-21). Moreover,
when comparing the proportion of clonal/subclonal losses
and gains across tumor types, the prostate and lung sam-
ples are statistically indistinguishable (corrected P-values
of 0.49 and 0.365, respectively). Overall, this suggests that
temporally distinct mechanisms lead to loss and gain
across the three tumor types. In terms of PMs, prostate
cancer exhibits more subclonal events than melanoma,
suggesting a more central role of PMs in melanoma onco-
genesis compared with prostate cancer, as confirmed
on an independent cohort from The Cancer Genome
Atlas (TCGA) of 264 melanoma samples (Figure S6B
in Additional file 8). However, aggregated values reflect
only part of the story as great variability in the percentage
of clonal events within a single combination of tumor and
aberration is observed (Figure S6C in Additional file 8).
We found no association between the patients’ clinical
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(Table S3 in Additional file 5).
Having assessed the variability in the clonality status of
aberrations in individual patients, we then evaluated how
it distributes along the whole genome as represented in
clonality circos plots (Figure 6A). We can appreciate com-
monality among the three tumor types in some specific
genomic regions. Genes on 8p are found clonally deleted
in 96%, 100%, and 100% of the prostate, melanoma, and
lung samples, respectively. They include the prostate
cancer suppressor NXK3-1 [19], the gene CSMD1,
which is recurrently deleted in melanoma [11], and the
phosphatase DUSP4, which is involved in negative feedback
control of EGFR signaling in lung adenocarcinoma [20].
Figure 4 In silico and in situ validation. (A) Coverage of overlapping aberrant and non-aberrant reads at the REARR breakpoints of clonal
TMPRSS2-ERG REARRs in two prostate adenocarcinomas (cases P03-2345 and PR-09-146). Upon removal of admixed DNA reads (gray), local coverage of
aberrant and non-aberrant reads match (AP close to 0.5), supporting the clonality of the rearrangement. (B) Representative case (PR-2525) with MSR1
subclonality REARR, validation by FISH. Low power view of prostate adenocarcinoma, Gleason score 3+4=7 in a prostatectomy specimen (black box).
Some areas do not have deletion of MSR1 as demonstrated by the presence of two yellow signals in tumor nuclei (yellow box). Other areas show
hemizygous deletion of MSR1 as demonstrated by the presence of only one yellow signal in tumor nuclei (blue box). Occasional nuclei with wild-type
MSR1 (arrow heads) are identified in this area. Nuclei with MSR1 hemizygous deletion comprised approximately 30% of assessed tumor areas. (C) A
homozygous subclonal deletion including CHD1 is inserted within a large hemizygous clonal deletion (case PR-2741). Cancer AF highlights the different
proportion of aberrant reads in the two cases. (D) Representative case with CHD1 subclonality (case PR-2741), validation by FISH. Low power view of
prostate adenocarcinoma, Gleason score 4+3=7 in a prostatectomy specimen. Some areas have homozygous deletion of CHD1 as demonstrated by
the presence of only two green signals (reference probe) in tumor nuclei (bottom left blue box). In contrast, other areas show hemizygous deletion of
CHD1 as demonstrated by the presence of one red (CHD1) and two green signals (reference probe) in tumor nuclei (bottom right black box). Note the
presence of two red and two green signals (wild-type CHD1) in adjacent stromal cells, used as internal control (arrow heads).
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Figure 5 Clonality comparison across somatic aberrations and tumor types. (A) Summary of clonality: clonality inference of genomic
events. Pie charts indicate the mean numbers of events classified as clonal (green) or subclonal (blue) across samples. (B) Statistics of clonality:
within tumor type and across tumor type comparisons of the proportion of the mean number of clonal/subclonal genomic events. Radar charts
report the statistics of the comparisons (P-values of the proportion test with Benjamini-Hochberg FDR correction). Dark gray continuous line
represents 99% confidence level.
Figure 6 Clonality distribution along tumor genomes. (A) For each tumor type the circos plot represents the distribution of clonality along
the genome. Each circos plot has five data tracks. The two outermost tracks report the proportion of clonal/subclonal losses and gains,
respectively. Then, PM APs and the associated clonality status are depicted in the middle track. Finally, the inner tracks show the clonality status
of intra- and inter-chromosomal REARRs. (B) Comparison of the clonality status of losses along chromosome 10q across tumor types. For each
tumor type, the clonality status of losses was sampled every 100 kb and the proportion of clonal/subclonal losses reported.
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highlight tumor-specific mechanisms of deregulation. Our
comparative analysis shows that although PTEN deletion
is involved in many cancer types, the underlying timing of
alteration may be different among tumor types (Figure 6B),
and may point to differential roles for pathway inactiva-
tion. Specifically, the focal and subclonal deletion in the
prostate samples suggests that evolutionary pressure is
acting in this region later in the natural history of the
disease and may promote cancer progression at a later
stage of cancer evolution. In contrast, the broad and
clonal deletion of a large part of chromosome 10q found
in melanoma indicates that PTEN is homogenously lost
in metastatic melanoma. In lung adenocarcinomas loss
of PTEN expression in EGFR-mutant cells correlates
with increased drug resistance [21], but the rarity of the
deletion observed entails the hypothesis that loss of ex-
pression is not due to a genomic alteration of PTEN.
Finally, our tool can also identify tumor lineage-specific
subclonality. MUC4, encoding a protein acting to upregu-
late cell cycle inhibitor p27 through ERBB2 phosphoryl-
ation [22] and mutated in melanoma [11], is subclonal
in the majority of samples (7 out of 12, 58%) on a back-
ground mean subclonality rate of 14% (Figure 5A)
(adjusted binomial test P-value <0.05); this is similar
for MUC2 and PCMTD1.T h eSOX2 gene, which encodes
a transcription factor relevant to lung development and
has been identified as a lineage-survival oncogene in lung
squamous cells carcinomas [23] and over-expressed in
advanced tumors [24], is detected as a subclonal gain in
one (case LUAD-AEIUF) of two amplified samples, with
possible implications for prognosis and risk stratification.
Clonal hierarchy of genomic aberrations
We next analyzed the temporal evolution of driver aberra-
tions [25,26] to build evolution maps (Figure 7A) capitaliz-
ing on the information from multiple individuals’ samples
in the absence of multiregion samples from the same indi-
vidual [27]. Given the study sample size and the mutation
frequencies, we built drafts of evolution maps by imple-
menting the following rules. An arrow from aberration A1
to aberration A2 is drawn if (i) A1 and A2 co-occur in at
least two samples, (ii) A1 preceded A2 in at least one sam-
ple, and (iii) A2 does not precede A1 in the considered
dataset (Figure 7A).
Extended analysis of the prostate tumors for which de-
letion evolution paths were provisionally characterized
[10] confirmed the temporal relation between the dele-
tion of PTEN and TMPRSS2-ERG rearrangements (both
via deletions and insertions in patient P01-28) in a co-
herent analysis framework. In addition, the improved
sensitivity of CLONET now identifies additional genes
whose loss precedes the homozygous deletion of CHD1,
namely NKX3-1, FOXO1, and RB1 (Figure 7A). To find
support for the observed relations, we further analyzed
203 independent localized prostate cancer samples that
underwent WES, including the Barbieri et al. dataset [17]
and the interim TCGA prostate cancer cohort. We veri-
fied the vast majority of the relations depicted in Figure 7A
(exceptions are BRCA2 with FOXO1 and RB1). It is worth
mentioning that no contradictory relations were detected.
In addition, in a set of patients treated with brachytherapy
[28], we verified through FISH analysis that PTEN subclo-
nal deletion is preferentially observed in the setting of
ERG rearrangement in line with other recent studies [29].
By querying recently reported gene sets [30,31] and high
confidence driver genes [32], the melanoma sample ana-
lysis revealed that clonal gains over chromosome 8q, in-
cluding the proto-oncogene MYC, precede a missense
mutation of NF1, a negative regulator of RAS signaling
[30], and that deletions on 6q spanning the pro-apoptotic
factor BCLAF1 (Bcl2-associated factor 1) consistently pre-
c e d em i s s e n s em u t a t i o n so fNBPF10 (chromosome 1q21.1)
and RANBP2 (chromosome 2q12.3).
Similarly, we considered 32 high confidence driver genes
[32] in the lung adenocarcinoma set (Figure 7A). CLONET
identified a path that stems from the clonal aberration of
gene FBN2 [33], either via deletion or missense mutation.
FBN2 disruption precedes the subclonal deletion of genes
along chromosome 9p, including significantly mutated
known lung adenocarcinoma genes SMARCA4, KEAP1,
and STK11 [12]. Interestingly, two paths involving differ-
ent aberration mechanisms appear to lead to 9p deletion:
(i) a direct path when the FBN2 gene is deleted; and (ii) an
indirect one through the loss of the 3p21.31-22.1 genomic
region in the case of a missense mutation of FBN2.
In order to investigate common patterns of progression
across tumor types, we interrogated a large set of putative
cancer genes (N=507; September 2013 version of COS-
MIC cancer gene census [34]) and applied pairwise inter-
sections (three supporting samples across the two tumor
types) of identified paths (Additional file 9). Despite the
conservative approach and the overall limited number of
samples, we observed that RB1 loss is consistently sequen-
tial to 6q losses in both melanomas and prostate cancers.
Similarly, aberrations along 17q (TP53) are followed by
NFKB2 loss, supporting additional oncogenic effects [35].
The same cluster of 17q gene aberrations precedes dele-
tions along 12q24 in both prostate and lung samples. Last,
we detected consistent subclonal deletions on 9q in both
melanoma and lung samples following deletions on 15q
and IRF4 gain. Notably, the path included a subclonal de-
letion of the tumor suppressor TSC1 (tuberous sclerosis 1)
that may activate the mammalian target of rapamycin
(mTOR) pathway and promote tumor development [36].
Finally, we explored the evolution of known cancer
signaling pathways (Figure 7B); both common themes
across tumor types and tissue-specific patterns emerged.
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detected as early drivers, such as androgen signaling in
prostate cancer, core mitogen-activated protein kinase
(MAPK) pathway components (such as BRAF) in melan-
oma, and p53 and EGFR in lung cancer. Interestingly,
although disruption of the same oncogenic pathways
may be implicated across the three tumor types, the
timing of dysregulation along the evolutionary paths
can be independent.
Discussion
We have developed a mathematical model that exploits
the genetic background of each individual to characterize
cancer cell heterogeneity within a tumor specimen and
builds lesion hierarchies by learning from recurrent pat-
terns across multiple patients. The approach relies on
base level information from a range of next-generation
sequencing data (WGS, WES and targeted sequencing)
and utilizes a local optimization approach and confidence
propagation steps to enable the processing of complex
subclonal patterns typical of patients with advanced tu-
mors who may have undergone multiple treatment cycles.
The local optimization approach ensures accurate
tumor purity assessment across challenging samples.
Our group recently implemented CLONET in precision
medicine WES reports to assess adequacy of biopsy
samples, highly relevant in a regulatory compliant envir-
onment. Direct assessment of CLONET performance
on WES versus WGS data from 15 samples (data from
[10,17]) showed excellent agreement for Adm.global
(Figure S8A in Additional file 10) and clonality esti-
mates (Figure S8B in Additional file 10) where 97.6% of
genes annotated as subclonal in WES are also subclonal
in WGS. This approach can also be utilized to assess
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Figure 7 Observed tumor patterns. (A) Draft tumor evolution paths of putative driver aberrations based on recurrent patterns. Thicker
arrows in the prostate path correspond to precedence relations that were confirmed in an independent cohort of 203 WES prostate samples.
(B) Draft tumor evolution paths based on cancer pathways. Each node represents a set of genes (aka a pathway). For a pair of pathways P1
and P2, CLONET computes the number of dependencies from each gene in P1 to each gene in P2,d 12, and the inverse, d21. If there is no
dependency between P1 and P2, then it is expected that d12 and d21 are statistically comparable (that is, d12 is generated from a symmetric
binomial distribution with d12 +d 21 trials). If d12 >d 21 and the P-values of the binomial test with Benjamini-Hochberg FDR correction is <0.01,
then the arc is reported.
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as observed with patient 7520, in which both his primary
untreated prostate cancer and metastatic treatment-
resistant tumor (biopsied three years later) were pro-
filed. Upon correction for ploidy and global admixture,
CLONET identified the gene AURKA as copy number
neutral in the primary sample but found a gain of two
copies in the late metastatic sample (Additional file 11).
Amplification of AURKA has been described in treatment-
resistant metastatic prostate cancer [29,37], and inhibitors
of AURKA are currently in clinical trials. In addition, by
exploiting the local optimization approach, we were suc-
cessful in following tumor dynamics across cell-free DNA
samples (liquid biopsies) from castration-resistant prostate
cancer patients upon deep targeted sequencing and to
monitor clonal expansion and contraction of key somatic
aberration from low tumor content DNA samples [38].
Here, we report the results from three common solid
tumor types characterized by diverse histology and clinical
course and for which we were able to detect patterns and
dynamics of subclonal evolution that support the rele-
vance of the approach. Globally, we observed great
variability across and within tumor types. Targeted ana-
lyses revealed both commonalities and clear differences
(Figure 6A). Notably, we identified the partial loss of
chromosome 8p as a common early event in the three
tumors, while the focused analysis on the long arm of
chromosome 10 suggested different mechanisms of PTEN
deregulation and participation in tumorigenesis. Finally,
specific examples of subclonality, such as MUC4 PMs in
melanoma and SOX2 gains in lung, have been identified.
Understanding patterns of tumor evolution can aid in the
rational development of more effective and early thera-
peutic approaches to directly target clonal events that
are driving tumorigenesis, especially as multiple poten-
tially actionable alterations are often identified within
one tumor even at diagnosis.
It is important to note that to properly construct com-
prehensive tumor evolution maps, thousands of genomes
are required to reach adequate statistical power when con-
sidering the range of frequencies of co-occurring aberra-
tions. As sequencing data for multiple tumor samples and
tumor types becomes accessible to the community, maps
will be drafted and completed over multiple iterations.
In turn, this will soon allow assigning an evolution time
stamp to each new clinically profiled sample based on
where the tumor genome fits into the evolution maps.
Establishing a 'timeline' of cancer progression is critical
for biomarkers development in the precision medicine
era, allowing clinicians to more accurately gauge prog-
nosis by adding a molecular measure of progression to
standard staging and grading systems, which do not asso-
ciate with molecular heterogeneity of samples (Table S3 in
Additional file 5). Such an approach may allow improved
clinical decision-making in a variety of cancer types,
guiding the choice of management strategies and level
of aggressive therapy based on how far the tumor has
progressed at the genomic level.
In summary, we present a robust method that exploits
next-generation sequencing data to classify somatic
lesions based on their clonality within the tumor cell
population. The utility of CLONET is related to transi-
tioning next-generation sequencing efforts from the
static evaluation of untreated tumor samples to the clin-
ical arena of precision medicine where patients will be
followed along a continuum of treatment modalities and
a targeted therapy regimen is based on the understand-
ing of driver mutations.
Conclusions
Distinguishing gatekeeper or driver mutations from pas-
senger mutations is a high priority for understanding
disease progression. Knowledge of the chronology of
molecular alterations can provide important insights into
defining the most clinically relevant mutations that
characterize important milestones in cancer. Genome
sequencing of cancer samples taken during the course
of precision medicine might demonstrate a wider range
of genomic heterogeneity than previously observed in
international genome sequencing studies. These clin-
ical samples demonstrate more heterogeneity and ad-
mixture of both tumor and non-tumor components.
To aid in unraveling the critical temporal evolution of
somatic aberrations in challenging clinical tumors, we
developed CLONET, a computation tool that requires
only few clonal events to precisely estimate tumor purity
and ploidy and then nominates the hierarchy of genomic
aberrations. We demonstrate that CLONET can deter-
mine the clonality of different types of somatic aberra-
tions, including SCNAs, PMs, and REARRs, using either
WGS or WES datasets. We anticipate that with the emer-
gence of larger genomic datasets, CLONET could help
map out the evolution of molecular alterations.
Materials and methods
CLONET pipeline
A schematic view of the CLONET pipeline is shown in
Figure S10A in Additional file 12. For this study input
data were obtained as follows. Read counts of informative
SNPs were extracted from BAM files using an in-house
procedure, SCNAs were detected using SegSeq [39] from
tumor and normal sequencing-based data, PM coordi-
nates were as in original corresponding manuscripts, and
REARRs were identified by means of dRanger and Break-
pointer [14]. Finally, to avoid germline background effects,
we filtered out genes (approximately 4,000) that intersect
significant (size greater than 2 kb) known germline copy
number variants [40].
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To assess genomic deletion, disruptive translocations or
polyploidy we used locus-specific dual-color FISH assays
following a previously described approach [41,42]. To
assess subclonality, at least 200 nuclei per area were
evaluated using a fluorescence microscope (Olympus
BX51; Olympus Optical, Tokyo, Japan). The probes used
for FISH assays were: SPRY2, 5′ RP11-51 N22 to 3′
RP11-478 F4; MSR1, 5′ RP11-6O24 to 3′ RP11-794E24;
ERG, 5′ BAC RP11-372O17 to 3′ BAC RP11-24A11; ref-
erence probe on 10q25, BAC RP11-431P18).
CLONET on exome and targeted sequencing data
The local approach implemented in CLONET enables
the analysis of samples with few SCNAs provided that
informative SNP read counts and Log R values are avail-
able. As with WGS data, individual specific informative
SNPs can be identified from matched normal DNA sam-
ples. Appropriate Log R values for exome genomic seg-
ments or for each targeted area can be obtained with
platform-specific strategies and provided to CLONET as
input. Specifically, in the case of exome data, array-based
segmented data or SCNA segments directly inferred from
exome data with recent well-performing tools [43] can be
utilized. CLONET combines segment input with exome-
derived read counts to estimate purity and ploidy and then
nominate subclonal aberrations based on sequencing data.
In the case of targeted sequencing data, copy number calls
derived using custom control regions and very high cover-
age (>1,000X) [38] allowed for CLONET-based clonality
estimation even in the case of low tumor content (<10%).
Expected distribution of the allelic fraction of a genomic
segment
Consider a genomic segment that spans a set of inform-
ative SNPs for the individual of interest. For any such SNP
with coverage cov, the total number of reads r supporting
the reference base (reference reads) is the sum of the neu-
tral reads (rn) and the active reads (ra) supporting the ref-
erence base. We define β as the ratio between neutral
reads and the total number of reads spanning the SNP of
interest. The probability of having k reference reads is
then defined as the convolution of the probability of ob-
serving β*k neutral reads and (1 - β)*k active reads, that is:
Pr¼ k;0≤k≤cov ðÞ ¼ Conv P rn ¼ β k ðÞ ;Pr a ¼ 1−β ðÞ   k ðÞ ðÞ
ð2Þ
We assume that P(rn =β *k) follows a binomial distri-
bution with number of trials equal to β*cov and prob-
ability of success equal to ps (that is, the probability to
observe a reference read). Note that ps may deviate from
0.5 due to read-mapping biases [44]. All the active reads
either support the reference base or the alternative base
as only one allele is represented by definition of active
reads. We define Nref as the proportion of informative
SNPs within the aberration that carry the SNP reference
base in the allele represented by active reads (active allele).
Then, the distribution P(ra=(1−β)*k) follows a categor-
ical distribution with values equal to Nref if ra =( 1 −β)*k
and equal to (1 - Nref)i fra=0.Eq uati on2ca nbewrit te n
in a closed form as the sum of two binomial distributions
(proof in Additional file 1):
P

r ¼ kjcov;β;Nref;psÞ¼ 1−Nref

 B

kjβ cov;psÞ
þNref  Bk − 1−β ðÞ  cov β cov;psÞ j ð
ð3Þ
where B(m|n,p) is the probability mass function of a bino-
mial distribution, that is, the probability of m successes in
n trials with success probability P.
Estimated proportion of neutral reads for a genomic
segment
The unknown values β and Nref of Equation 3 can be in-
ferred from the sequencing coverage at informative SNPs
within the considered segment. In particular, given a seg-
ment Seg and a set I of informative SNPs within Seg,e a c h
informative SNP in I is a sample from the distribution of
Equation 3. Optimization can be used to determine the
values of β and Nref for each segment. Given a random
pair (β, Nref), the Kolmogorov-Smirnov nonparametric
goodness-of-fit test for discrete null distribution [45] com-
putes the likelihood that the informative SNPs in I are a
sample from P(r=k|c,β, Nref,ps). Next, a particle swarm
optimization method [13] finds a candidate pair ^ β; ^ N ref
that best represents the distribution of the allelic fraction
of the SNPs in I.
From neutral reads to non-aberrant reads
Consider a genomic segment Seg.I ft h eL o gRv a l u eo fSeg
supports a SCNA C, we define as aberrant those reads
that cover Seg and are sequenced from cells harboring C.
If Seg is a candidate somatic mono-allelic deletion, the
percentage of neutral reads β corresponds to the percent-
age of reads that cover Seg and are sequenced from cells
harboring both alleles, that is, neutral and non-aberrant
reads correspond. If the Log R value of Seg supports a gain
with integer copy number cn >2,weha v etore -s ca leβ to
obtain the percentage of sequenced cells that have copy
number cn (that is, the percentage of non-aberrant reads).
For the sake of simplicity, we reason in terms of at most
one copy difference between alleles. If cn is odd, the
number of neutral reads is the sum of the neutral reads
from admixed cells plus the neutral reads of the gain
(Figure S10B in Additional file 12). The percentage βcn
of reads from cells with copy number cn is computed
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neutral reads due to the gain, that is:
βcn ¼ 1−cnG  1−β ðÞ ð 4Þ
If cn is even and at most one copy difference between
alleles is allowed, then β is close to one, as both alleles
are equally represented. This reasoning applies to any arbi-
trary combinations of the number of alleles (Figure S10C
in Additional file 12).
From aberrant reads to aberrant cells
Given a somatic mono-allelic deletion M, the local admix-
ture Adm.local is defined as the proportion of cells not
harboring M (non-aberrant cells) over the total number of
cells. Let a define the total number of reads supporting
the alternative allele (alternative reads), as the sum of neu-
tral reads (an) and active reads (aa) supporting the alterna-
tive base. For any informative SNP within M,t h el o c a l
admixture at M results:
Adm:localM ¼
rnþan
2
rnþan
2 þ ra þ aa ðÞ
ð5Þ
and the proportion of non-aberrant reads covering M is:
βM ¼
rn þ an
rn þ an þ ra þ aa
ð6Þ
By combining Equations 5 and 6, we can prove
Equation 1. Additional file 1 reports a full proof of a gen-
eralized version of Equation 1 that accounts for any posi-
tive copy number.
Uncertainty assessment and its propagation to clonality
estimates
Different error sources introduce a bias into the distri-
bution of the allelic fraction that may lead to inaccurate
estimates of β. To optimize sensitivity and specificity, we
compute the estimation uncertainty ε around β and we
provide a sound way to propagate ε to clonality values.
The value of ε varies based upon the depth of sequence
mean coverage (mean.cov) and the number of available
informative SNPs (n.info.snp) across the segment of
interest in the sample considered. The mean.cov controls
the ability to discern the two modes of the AF distribu-
tion: the inset of Figure 2A shows that the higher β is,
the more coverage is needed. We evaluated the uncer-
tainty in β estimates as a function of these parameters
by randomly generating 50 samples with given mean.cov,
n.info.snps, and β and averaging the difference between
the expected and computed β for a given coverage and
number of SNPs. Accordingly, we generated a look-up
uncertainty table for each combination of mean.cov and
n.info.snps (Figure 3A).
The procedure to infer the value of β of a segment is
independent of its Log R value. Interestingly, if we plot
the Log R of a segment versus its value of β, segments
aggregate into clusters, where each cluster corresponds
to a specific copy number and to a definite clonality sta-
tus (Figure S10C in Additional file 12). If we restrict our
attention to putative somatic mono-allelic deletions, the
cluster Bmin with the lowest median value of β would
likely represent 100% clonal deletions. CLONET relies
on an uncertainty table (Figure 3A) to characterize Bmin.
We define B as the set of β values of all the putative
somatic mono-allelic deletions and err(β) as the uncer-
tainty around β. In this context, Bmin is defined as the
smallest subset of B such that min(B) in Bmin and for all
β’ in B and not in Bmin, max(Bmin)+err (max(B min))<β’–
err(β’). CLONET starts from min(B) and searches for a
β’ value such that their difference is not explained by
the error table. Then, CLONET selects the median value
of Bmin as candidate Adm.global and computes the uncer-
tainty around Adm.global as the minimum and the max-
imum of the λ percentage of the distribution of Bmin.T h e
value of λ depends on the noise observed in the coverage
(in this study we set λ equal to 95%).
G i v e nas o m a t i cc o p yn u m b e rC in a tumor sample,
CLONET computes its local (Adm.localC)a n dg l o b a l
(Adm.global) admixture. The clonality ClC of C is then
defined as the percentage of tumor cells in a sample
harboring C:
ClC ¼
1− Adm:localC
1−Adm:global
ð7Þ
The more the value of Adm.localC differs from the esti-
mated global admixture Adm.global, the more C is subclo-
nal, namely the value of ClC approximates to 0. Finally,
interval analysis [46] allows propagating uncertainty
around β and Adm.global to clonality (Figure S10D in
Additional file 12).
Clonality of bi-allelic deletions
Equation 7 enables us to compute the percentage of
tumor cells harboring any specific aberration (that is, its
clonality) except for clonal bi-allelic deletions. For sub-
clonal bi-allelic deletions the allelic fraction signal comes
from cells with either two or one allele (Additional file 2).
Consider a subclonal bi-allelic deletion where n (normal),
m (mono-allelic), and b (bi-allelic) denote the proportion
of cells with two, one, and zero alleles, respectively (n+m+
b=1). By Equation 1 one can assess a local estimate of the
admixture (Adm.local) that represents the proportion of
cells with two alleles in the subpopulation of cells with
one or two alleles, that is n=Adm.local*(n+m). We can
also observe that the proportion of normal cells n in the
sample is equal to the global DNA admixture Adm.global.
Prandi et al. Genome Biology 2014, 15:439 Page 12 of 16
http://genomebiology.com/2014/15/8/439Finally, we define the clonality of a bi-allelic deletion ClB
as the percentage of cells harboring a bi-allelic deletion
over the number of cells with a mono- or a bi-allelic dele-
tion, that is, b/(m+b). One can prove (Additional file 1)
that the clonality Clb of a bi-allelic deletion is:
Clb ¼
Adm:global − Adm:local   Adm:global
Adm:local   1− Adm:global ðÞ
ð8Þ
Data availability
Binary sequence alignment/map (BAM) files of WGS
data are accessible in the database of Genotypes and
Phenotypes (dbGaP) with accession numbers phs000447.
v1.p1 (prostate cancer [10]), phs000452.v1.p1 (melanoma
[11]), and phs000488.v1.p1 (lung [12]); BAMs of WES
data at dbGaP with accession number phs000447.v1.p1
(prostate cancer [17]).
CLONET source code
Source code is available at [47] and at the version-
controlled repository [48].
Additional files
Additional file 1: Supplementary text.
Additional file 2: Figure S1. Pictorial representation of the method
CLONET uses to manage bi-allelic deletions. Three types of cells are
considered: normal cells (yellow) with gene A (dark brown) and gene B
(light brown) present in two copies; tumor cells of type I (light red) harbor a
bi-allelic deletion of both genes A and B; tumor cells of type II (dark red)
have zero copies of B and one copy of A. The bottom row reports the
distribution of the expected AF at informative SNPs within gene A and gene
B. In pure diploid cells with two copies of genes A and B, AF is centered at
0.5. In type I tumor cells, there is no signal, as both alleles are deleted. In
type II tumor cells, one allele of gene B is present and the AF assumes
values 0 or 1. In a hypothetical mixture of normal and tumor cells (right
panel), the distribution of AFs along gene A reports only the signal from the
DNA admixture, while the distribution of gene B corresponds to a mono-allelic
deletion, reflecting the fact that cells with a bi-allelic deletion do not
contribute to the AF.
Additional file 3: Figure S2. (A-C) Histograms of the Log R data of all
the samples in the prostate (A), melanoma (B), and lung datasets (C). The
left plot shows data as reported by the segmentation algorithm while
the right plot shows Log R values after ploidy and Adm.global correction.
Log R correction improves the quality of the segmentation and simplify
the detection of copy number aberrations.
Additional file 4: Figure S3. (A) Comparison between alternative allele
proportions computed from WGS and MiSeq experiments. Scatterplot of
the alternative allelic proportion (AP) on 18 somatic point mutations in
prostate samples selected for MiSeq validation. The x-axis reports the AP
observed on MiSeq data and the y-axis reports the same value computed
on WGS data (Table S1 in Additional file 5). The color of a point corresponds
to the clonality assigned by CLONET to the point mutation. Inset text
reports Pearson product-moment correlation coefficient and associated
P-value. (B) Allelic fraction (AF) of informative SNPs along the interstitial
deletion between TMPRSS2 and ERG and of an independent control
clonal deletion for each sample reported in Figure 3A. The clonality
statuses of the REARRs and of the accompanying interstitial deletions
are identical.
Additional file 5: Table S1. Read count of selected point mutations for
MiSeq validation. Table S2. Pairwise comparison of the percentage of
subclonal genomic events relative to Figure 5C. Table S3. The association
between the percentage of subclonal genomic events when samples are
partitioned according to patient clinical characteristics. The table shows
that the clinical characteristics are not able to distinguish between less
and more heterogeneous samples.
Additional file 6: Figure S4. Experimental in situ validation. (A) Low
power view of adenocarcinoma Gleason score 3+ 3 = 6 in a
prostatectomy specimen representative case of prostate adenocarcinoma
with SPRY2 subclonality (case STID-3042). Some areas do not have deletion
of SPRY2, as demonstrated by the presence of two yellow signals in tumor
cells by FISH (yellow box). In contrast, other areas show hemizygous
deletion of SPRY2, as demonstrated by the presence of only one yellow
signal (blue box; arrow heads) in tumor cells by FISH. (B) Low power view
of prostate adenocarcinoma Gleason score 4+4=8 with tertiary Gleason
pattern 5 in a prostatectomy specimen from a representative case of prostate
adenocarcinoma with CHD1 subclonality (case STID 2525). Some areas have
homozygous deletion of CHD1 as demonstrated by the presence of only two
yellow signals (reference probe) in tumor cells by FISH (yellow box). In
contrast, other areas show hemizygous deletion of CHD1 as demonstrated
by the presence of one red (CHD1) and two yellow signals (reference probe)
in tumor cells by FISH (blue box). Note the presence of two red and two
yellow signals (normal) in adjacent stromal cells, used as internal control
(arrow heads).
Additional file 7: Figure S5. In silico validation. (A) Scatterplot of the
Adm.global estimates of CLONET (y-axis) versus those of ABSOLUTE
(x-axis). Each dot represents a WGS melanoma sample whose color
corresponds to the ploidy value estimated by ABSOLUTE. The plot shows
that the ploidy of a sample does not bias the estimation. Inset text
reports Pearson product-moment correlation coefficient and associated
P-value. (B) Scatterplot of the Adm.global estimates of CLONET (y-axis)
versus those of ABSOLUTE (x-axis) where each dot represents a WGS
prostate sample. Inset text reports Pearson product-moment correlation
coefficient and associated P-value. (C) Scatterplot of the Adm.global
estimates of CLONET (y-axis) versus those of ABSOLUTE (x-axis) where
each dot represents a WES prostate sample. Inset text reports Pearson
product-moment correlation coefficient and associated P-value. Ploidy
evaluation on the same dataset gives concordant values and found only
an aneuploidy sample (case 04-1243 L). (D) Scatterplot of the ploidy
estimates of CLONET (y-axis) versus those of ABSOLUTE (x-axis). Each dot
represents a WGS melanoma sample whose color corresponds to the
Adm.global value estimated by ABSOLUTE. The plot shows that the Adm.
global of a sample does not bias the estimation. Inset text reports Pearson
product-moment correlation coefficient and associated P-value. (E) A
melanoma case (ME049T) classified as having ploidy equal to 3.05 by
ABSOLUTE and equal to 1.93 by CLONET. The histogram (top) shows the
Log R distribution of the segments. Yellow, violet, and orange arrows
point to key Log R peaks used by both CLONET and ABSOLUTE for
ploidy estimation. Beta versus Log R plot (bottom) shows the observed
values for each genomic segment in sample ME049T (gray dots) and the
expected position given purity and ploidy estimated by CLONET and
ABSOLUTE (blue and green dots, respectively). Boxes show allele specific
copy number values defined by the position in the Beta versus Log R
space.
Additional file 8: Figure S6. (A) Summary of aberrations: genomic
events (GE) characterized in three tumor datasets generated through
whole genome sequencing. (B) Histogram of the alternative allelic
proportion after Adm.global correction of the copy number neutral
somatic point mutations detected in a cohort of 264 melanoma samples
from TCGA. Pie chart indicates the mean numbers of events classified as
clonal (green) or subclonal (blue) across samples. (C) Boxplot of the
percentage of clonal genes across GEs and tumor types with respect to
the total number of aberrant genes. Superimposed strip-charts represent
per sample data: the size of each dot is proportional to the number of
genes analyzed.
Additional file 9: Figure S7. Common evolution of cancer gene
aberrations across tumor samples. Pairwise intersection of the tumor
evolution paths of prostate, melanoma and lung samples computed on a
panel of 507 cancer genes. Nodes stand for aberrant genes with the
color representing the chromosome and the shape the kind of
Prandi et al. Genome Biology 2014, 15:439 Page 13 of 16
http://genomebiology.com/2014/15/8/439aberration. Arcs model temporal order between two aberrations found in
at least three samples of the two tumor types considered. The central
semicircle reports the dependencies found in the three tumor types.
Additional file 10: Figure S8. Comparison of WGS- and WES-based
estimates. (A) Scatterplot of the Adm.global estimates of CLONET on 15
prostate patients for which both exome data (y-axis) and WGS data
(x-axis) are available. Inset text reports Pearson product-moment correlation
coefficient and associated P-value. (B) Scatterplot of the percentage of
clonality estimated for 23,484 genes in 15 prostate samples computed using
exome data (y-axis) and WGS data (x-axis). Inset text reports Pearson
product-moment correlation coefficient and associated P-value.
Additional file 11: Figure S9. Case of tumor progression. (A,B) The top
part of the figure shows histograms of the Log R data for a primary
prostate sample (A) and a pelvic mass metastasis (B) from the same
patient. (C,D) Upon correction for ploidy and global admixture, CLONET
identifies gene AURKA as copy number neutral in the primary sample (C)
but found a gain of two copies in the late metastatic sample (D). (E) The
shift in the Log R values prior and after CLONET ploidy correction in the
metastatic sample indicates an aneuploidy genome, as confirmed by
FISH analysis that demonstrate four yellow signals (reference probe) in
tumor cells. The probes that were used for FISH assays are as follows: red
test probe, 3′ ERG (BAC RP11-24A11); reference probe, 10q25
(BAC RP11-431P18).
Additional file 12: Figure S10. CLONET method. (A) Schematic
overview of the computing steps that lead to the definition of the tumor
evolution path. (B) An example of a tumor specimen with two non-aberrant
cells (yellow) and three aberrant cells (blue) with a duplicated genomic
region (red). The Adm.global of this specimen is 2/5 and the percentage of
aberrant reads is 4/13. Note that these values respect Equation 1. The left
shows tumor cells that result from decomposing the blue aberrant cells into
three normal cells and three aberrant cells with a mono-allelic deletion
(brown). The percentage of neutral reads is 10/13. The value of β is rescaled
to account for the gain by considering the proportion of aberrant reads is
three times greater, that is, 1 - (3*(1 - β)). The bottom plot highlights that
the AF of the tumor specimen and of its decomposition are the same.
(C) Example of the distribution of the expected β versus Log R values in a
sample with 20% of Adm.global and a mean ploidy of 2. Each point
represents a genomic segment defined by its Log R value, computed
by segmentation, and its β value, computed by CLONET. In particular,
the blue cluster includes segments where only one allele is present in
100% of the tumor cell population (that is, they are mono-allelic clonal
deletions). These segments are used to compute the Adm.global of
the sample. The variability range of the Adm.global returned by
CLONET considers the dispersion of the data in this cluster. (D) The
plot shows how the variability ranges of local and global DNA admixture
estimates propagate to the clonality values. Each box corresponds to a pair
of local and global DNA admixture values and illustrates the clonality
variability range as a function of their variability ranges. Local and global
admixture variability ranges are computed from the β uncertainty table.
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